Paul A. Robiolio
Duke University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paul A. Robiolio.
Circulation | 1995
Paul A. Robiolio; Vera H. Rigolin; John Wilson; Harrison Jk; L. L. Sanders; Thomas M. Bashore; Jerome M. Feldman
BACKGROUND Although serotonin has been postulated as an etiologic agent in the development of carcinoid heart disease, no direct evidence for different ambient serotonin levels in cardiac and noncardiac patients has been reported to date. METHODS AND RESULTS The present study reviews our experience with 604 patients in the Duke Carcinoid Database. Nineteen patients with proven carcinoid heart disease (by cardiac catheterization and/or echocardiogram) were compared with the remaining 585 noncardiac patients in the database with regard to circulating serotonin and its principal metabolite, 5-hydroxyindole acetic acid (5-HIAA). No significant demographic differences existed between the cardiac and noncardiac groups; however, typical carcinoid syndrome symptoms (ie, flushing and diarrhea) were almost threefold more common in the cardiac group (P < .001). Compared with the noncardiac group, heart disease patients demonstrated strikingly higher (P < .0001) mean serum serotonin (9750 versus 4350 pmol/mL), plasma serotonin (1130 versus 426 pmol/mL), platelet serotonin (6240 versus 2700 pmol/mg protein), and urine 5-HIAA (219 versus 55.3 mg/24 h) levels. The spectrum of heart disease among the 19 patients showed a strong right-sided valvular predominance, with tricuspid regurgitation being the most common valvular dysfunction (92% by cardiac catheterization; 100% by echocardiogram). CONCLUSIONS These data suggest that serotonin plays a major role in the pathogenesis of the cardiac plaque formation observed in carcinoid patients.
American Journal of Cardiology | 1995
Paul A. Robiolio; Vera H. Rigolin; J. Kevin Harrison; James E. Lowe; Joseph O. Moore; Thomas M. Bashore; Jerome M. Feldman
The cardiac valvular surgical experience of patients in the Duke Carcinoid Database was reviewed to assess operative outcome. Of the 604 patients in the database, 19 patients with carcinoid heart disease were identified by cardiac catheterization or echocardiography, or both. Eight of these underwent tricuspid valve replacement surgery with bioprostheses (2 also had open pulmonic valvuloplasty). Compared with patients medically managed, surgically treated patients were similar with the exception that they had higher right atrial mean (17 +/- 6 vs 9 +/- 4 mm Hg, p = 0.03) and v-wave (27 +/- 6 vs 17 +/- 7 mm Hg, p = 0.04) pressures. Of the 8 surgical patients, 5 (63%) died within 30 days. Causes of death included tricuspid valve thrombosis, cerebral vascular accident, coagulopathy, renal failure, and intractable right heart failure. High comorbidity was present in all 8 patients. There was a weak trend (p = 0.17) toward lower Charlson comorbidity indexes in survivors (6.7 +/- 0.6) compared with nonsurvivors (7.6 +/- 0.9). Age was significantly lower (p = 0.036) in survivors (46 +/- 13 years) compared with nonsurvivors (69 +/- 4 years). Extended follow-up revealed 2 patients who survived beyond a decade. Review of 47 carcinoid valve replacement cases (Duke Carcinoid Database and 39 published cases) revealed a 30-day mortality of 56% for patients > 60 years of age, and 0% for those < or = 60 years of age (p < 0.0001). Although valve replacement surgery can afford prolonged palliation from carcinoid heart disease, it is associated with a significant mortality risk. Careful preoperative risk stratification by age and comorbidity may provide a means for optimal selection of surgical candidates.
American Journal of Cardiology | 1995
Paul A. Robiolio; Vera H. Rigolin; Steven E. Hearne; William A. Baker; Katherine B. Kisslo; Cynthia Pierce; Thomas M. Bashore; J. Kevin Harrison
EF in patients with aortic stenosis and reduced EF who underwent aortic valve replacement did not improve by 1 week postoperatively despite rectification of afterload mismatch. By 6 months, however, EF significantly improved without any further change in ventricular loading conditions. This implies that the benefit from aortic valve replacement (when measured by LV ejection performance) may not be evident until late postoperatively.
American Journal of Cardiology | 1997
Vera H. Rigolin; Michael Higgenbotham; Paul A. Robiolio; Steven E. Hearne; William A. Baker; Katherine B. Kisslo; J. Kevin Harrison; Thomas M. Bashore
Twenty-nine patients with moderate mitral stenosis and 29 age-matched normal controls underwent symptom-limited upright bicycle exercise testing with simultaneous hemodynamic monitoring. Exercise tolerance in the mitral stenosis group was found to be limited by inadequate cardiac output reserve and not by resting mitral valve area or exercise pulmonary capillary wedge pressure.
Catheterization and Cardiovascular Diagnosis | 1995
Vera H. Rigolin; Paul A. Robiolio; John Wilson; J. Kevin Harrison; Thomas M. Bashore
American Journal of Cardiology | 1997
Vera H. Rigolin; Jennifer S. Li; Michael W. Hanson; Martin J. Sullivan; Paul A. Robiolio; Steven E. Hearne; William A. Baker; J. Kevin Harrison; Thomas M. Bashore
American Journal of Cardiology | 1996
Vera H. Rigolin; Paul A. Robiolio; Laurence A. Spero; Brian P. Harrawood; Kenneth G. Morris; Donald F. Fortin; William A. Baker; Thomas M. Bashore; Jack T. Cusma
American Heart Journal | 1998
Paul A. Robiolio; Vera H. Rigolin; J. Kevin Harrison; Katherine B. Kisslo; Thomas M. Bashore
Journal of the American College of Cardiology | 1995
Paul A. Robiolio; Vera H. Rigolin; Eric B. Lieberman; John Wilson; Steven E. Hearne; Katherine B. Kisslo; Cynthia Pierce; Thomas M. Bashore; J. Kevin Harrison
Journal of the American College of Cardiology | 1995
Vera H. Rigolin; Michael B. Higginbotham; Paul A. Robiolio; John Wilson; James P. Shaw; Katherine B. Kisslo; J. Kevin Harrison; Thomas M. Bashore